公开(公告)号：US20250092042A1

公开(公告)日：2025-03-20

申请号：US18924066

申请日：2024-10-23

Applicant: NOVARTIS AG

Inventor： Mallesh BUSHABOINA ,  Xin CHEN ,  Atwood Kim CHEUNG ,  Andrew James CULSHAW ,  Timothy Brian HURLEY ,  Nancy LABBE-GIGUERE ,  Wolfgang MILTZ ,  David ORAIN ,  Tajesh PATEL ,  Srinivasan RAJAGOPALAN ,  Till ROEHN ,  David Andrew SANDHAM ,  Gebhard THOMA ,  Ritesh Bhanudasji TICHKULE ,  Rudolf WÄLCHLI

IPC: C07D471/10 ,  A61K45/06 ,  C07D519/00

Abstract: The present invention provides a method for manufacturing a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein R1 R2, R4 and X1 are defined herein.

公开(公告)号：US20210107889A1

公开(公告)日：2021-04-15

申请号：US17065360

申请日：2020-10-07

Applicant: NOVARTIS AG

Inventor： Amy CALHOUN ,  Xin CHEN ,  Kevin Matthew GARDINIER ,  Edward Charles HALL ,  Keith JENDZA ,  Nancy LABBE-GIGUERE ,  James NEEF ,  Daniel Steven PALACIOS ,  Ming QIAN ,  Michael David SHULTZ ,  Christopher G. THOMSON ,  Kate Yaping WANG ,  Fan YANG

IPC: C07D401/04

Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US20240140959A1

公开(公告)日：2024-05-02

申请号：US18497296

申请日：2023-10-30

Applicant: NOVARTIS AG

Inventor： Amy CALHOUN ,  Xin CHEN ,  Kevin Matthew GARDINIER ,  Edward Charles HALL ,  Keith JENDZA ,  Nancy LABBE-GIGUERE ,  James Anthony NEEF ,  Daniel Steven PALACIOS ,  Ming QIAN ,  Michael David SHULTZ ,  Christopher G. THOMSON ,  Kate Yaping WANG ,  Fan YANG

IPC: C07D491/107 ,  A61K45/06 ,  A61P25/18

CPC classification number: C07D491/107 ,  A61K45/06 ,  A61P25/18

Abstract: Provided herein are compounds according to Formula (I)




or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US20220411435A1

公开(公告)日：2022-12-29

申请号：US17818321

申请日：2022-08-08

Applicant: NOVARTIS AG

Inventor： Amy CALHOUN ,  Xin CHEN ,  Kevin Matthew GARDINIER ,  Edward Charles HALL ,  Keith JENDZA ,  Nancy LABBE-GIGUERE ,  James NEEF ,  Daniel Steven PALACIOS ,  Ming QIAN ,  Michael David SHULTZ ,  Christopher G. THOMSON ,  Kate Yaping WANG ,  Fan YANG

IPC: C07D491/107 ,  A61P25/18 ,  A61K45/06

Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US20220315578A1

公开(公告)日：2022-10-06

申请号：US17020114

申请日：2020-09-14

Applicant: NOVARTIS AG

Inventor： Xin CHEN ,  Marie-Line GOUDE ,  Edmund Martin HARRINGTON ,  Gregory John HOLLINGWORTH ,  Julien LORBER ,  Martin SENDZIK ,  Anna VULPETTI ,  Thomas ZOLLER

IPC: C07D471/04 ,  C07D401/14

Abstract: The disclosure provides BRD9 bifunctional compounds of Formula (A), (BF-I), (BF-II), (BF-III), (BF-IIIa), (BF-IIIb), (BF-IV), (BF-IVa), (BF-IVb), (BF-I′), (BF-II′), (BF-III′), (BF-IV′), or (BF-V′), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, to their preparation, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases and disorders mediated by a bromodomain-containing protein, such as bromodomain-containing protein 9 (BRD9).

公开(公告)号：US20210130365A1

公开(公告)日：2021-05-06

申请号：US17065367

申请日：2020-10-07

Applicant: NOVARTIS AG

Inventor： Amy CALHOUN ,  Xin CHEN ,  Kevin Matthew GARDINIER ,  Edward Charles HALL ,  Keith JENDZA ,  Nancy LABBE-GIGUERE ,  James NEEF ,  Daniel Steven PALACIOS ,  Ming QIAN ,  Michael David SHULTZ ,  Christopher G. THOMSON ,  Kate Yaping WANG ,  Fan YANG

IPC: C07D491/107 ,  A61K45/06 ,  A61P25/18

Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US20240360137A1

公开(公告)日：2024-10-31

申请号：US18442235

申请日：2024-02-15

Applicant: Novartis AG

Inventor： Karin BRINER ,  Xin CHEN ,  Sajan JOSEPH ,  Vivek RAUNIYAR ,  Frédéric ZECRI

IPC: C07D487/04 ,  A61K31/519 ,  C07D519/00

CPC classification number: C07D487/04 ,  A61K31/519 ,  C07D519/00

Abstract: The invention relates to compounds which inhibit CDK2 (Cyclin-Dependent Kinase 2 or Cell Division protein Kinase 2), and to processes for the preparation of said compounds, pharmaceutical compositions comprising said compounds, and use of said compounds in the treatment of conditions, diseases and disorders mediated by CDK2.

公开(公告)号：US20240043425A1

公开(公告)日：2024-02-08

申请号：US18319585

申请日：2023-05-18

Applicant: NOVARTIS AG

Inventor： Mallesh BUSHABOINA ,  Xin CHEN ,  Atwood Kim CHEUNG ,  Andrew James CULSHAW ,  Timothy Brian HURLEY ,  Nancy LABBE-GIGUERE ,  Wolfgang MILTZ ,  David ORAIN ,  Tajesh PATEL ,  Srinivasan RAJAGOPALAN ,  Till ROEHN ,  David Andrew SANDHAM ,  Gebhard THOMA ,  Ritesh Bhanudasji TICHKULE ,  Rudolf WÄLCHLI

IPC: C07D471/10 ,  A61K45/06 ,  C07D519/00

CPC classification number: C07D471/10 ,  C07D519/00 ,  A61K45/06

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof;






wherein R1 R2, R4 and X1 are defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20230212139A1

公开(公告)日：2023-07-06

申请号：US18062356

申请日：2022-12-06

Applicant: NOVARTIS AG

Inventor： Amy CALHOUN ,  Xin CHEN ,  Kevin Matthew GARDINIER ,  Edward Charles HALL ,  Keith JENDZA ,  Nancy LABBE-GIGUERE ,  James NEEF ,  Daniel Steven PALACIOS ,  Ming QIAN ,  Michael David SHULTZ ,  Christopher G. THOMSON ,  Kate Yaping WANG ,  Fan YANG

IPC: C07D401/04

CPC classification number: C07D401/04 ,  A61K45/06

Abstract: Provided herein are compounds according to Formula (I)




or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.